All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
HMA + venetoclax + IDH inhibitors in ND IDH-mutated AML: A pooled analysis
Results from a pooled analysis evaluating outcomes in 60 patients with newly diagnosed (ND) IDH-mutated acute myeloid leukemia (AML), ineligible for intensive chemotherapy (IC), treated with a triplet regimen containing azacitidine or decitabine + venetoclax + ivosidenib or enasidenib were published by DiNardo et al. in the Journal of Clinical Oncology.
Key data: At a median follow-up of 27.4 months, the composite complete remission (CRc) rate and overall response rate (ORR) were 92% and 95%, respectively. The median overall survival (OS) was not reached. The 2-year OS and cumulative incidence of relapse (CIR) rates were 69% and 24%. The triplet isocitrate dehydrogenase (IDH) regimens were well tolerated with low early mortality (2%).
Key learning: The IDH triplet regimen improved outcomes in IC-ineligible patients with ND IDH-mutated AML. Future studies comparing outcomes of IDH-triplet vs IDH-doublet regimens will further strengthen the evidence for these novel combinations.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
When choosing treatment for patients with AML, how much is your selection influenced by your personal experience with a treatment’s safety profile?
